Ceritinib + Nivolumab for Non-Small Cell Lung Cancer
Trial Summary
What is the purpose of this trial?
This is an open label multi center trial to determine the safety and efficacy of ceritinib in combination with nivolumab in ALK-positive NSCLC patients
Research Team
Novartis Pharmaceuticals
Principal Investigator
Novartis Pharmaceuticals
Eligibility Criteria
This trial is for adults with ALK-positive Non-Small Cell Lung Cancer (NSCLC) who may have had previous cancer treatments but recovered from most side effects. They should have at least one measurable tumor and be in good physical condition (WHO performance status 0-1). People with other recent cancers, autoimmune diseases, difficulty swallowing pills, or severe medical conditions can't participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive ceritinib in combination with nivolumab
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Ceritinib
- Nivolumab
Ceritinib is already approved in United States for the following indications:
- High-risk neuroblastoma in the bone or bone marrow
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novartis Pharmaceuticals
Lead Sponsor
Dr. Vas Narasimhan
Novartis Pharmaceuticals
Chief Executive Officer since 2018
MD from Harvard Medical School
Dr. Shreeram Aradhye
Novartis Pharmaceuticals
Chief Medical Officer since 2021
MD